March 2, 2026
Photo provided by EssilorLuxottica
PARIS — EssilorLuxottica recently presented at two scientific forums in Hong Kong—the Collaborative Community on Ophthalmic Innovation (CCOI) Asia-Pacific Innovation Forum 2026 and the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress. The company’s goal at both events was to advance scientific dialogue on the future of myopia management and ophthalmic innovation. Discussions reflected a shift in myopia management, from slowing progression alone to a broader, prevention-focused and future-oriented approach grounded in clinical evidence and collaboration.
Advancing the Next Frontier in Myopia Management
During Myopia Day at CCOI, Dr. Norbert Gorny, Chief Scientific Officer of EssilorLuxottica, discussed the industry’s instrumental role in expanding the myopia toolkit. He outlined a long-term scientific ambition that builds on today’s first-line solutions for slowing progression and looks toward next frontiers, including research exploring the potential to ultimately stop progression and prevent or significantly delay myopia onset. He also emphasized access, standards of care, collaboration and AI-enabled innovation.
Co-chairing a session on lens-based innovation, Olga Prenat, Global Head of Medical and Professional Affairs at EssilorLuxottica, shared clinical perspectives on spectacle-based myopia management. She emphasized the importance of evidence-based optical interventions within a comprehensive prevention and progression management strategy. She highlighted emerging approaches to delay myopia onset and improve efficacy across the continuum of care, referencing Essilor Stellest lens.†
On Innovation Day, Kfir Azoulay, Managing Director of Heidelberg Engineering, part of EssilorLuxottica, described what the industry must do now to transform glaucoma’s trajectory. He tackled key challenges at the intersection of myopia and glaucoma, emphasizing early diagnostic challenges and the need for interoperable, multi-site data. He further referenced collaborative initiatives such as the Glaucoma Myopia OCT Phenotyping Consortium (GMOPC), which addresses the clinical reality that high myopia can confound glaucoma assessment and complicate OCT interpretation.
From Clinical Evidence to the Future of Myopia Management
At EssilorLuxottica’s sponsored symposium at APAO, Prof. Mark Bullimore presented a structured clinical roadmap for myopia management. His discussion emphasized early risk identification and personalized treatment based on axial elongation. Dr. Peter Chen presented two-year data from a randomized clinical trial in pre-myopic children using H.A.L.T.* technology, highlighting reduced axial eye growth with higher wearing time.
Olga Prenat also outlined a comprehensive, evidence-based approach to myopia management, reinforcing clinical practice across the continuum of care. Dr. Björn Drobe, Director of Applied Myopia Research (R&D) at EssilorLuxottica, presented the optical design, H.A.L.T.* MAX technology and clinical evidence behind Essilor Stellest 2.0 lenses.‡ Results from a 12-month randomized contralateral crossover clinical trial in Singapore demonstrated significantly greater efficacy of Essilor Stellest 2.0 lenses in slowing eye growth in myopic children compared with Essilor Stellest lenses,†,§,1 almost halving elongation versus the previous generation.¶,1
“Our contributions reflected a shift in myopia management, from slowing progression alone toward a broader, prevention-focused and future-oriented approach. Through scientific collaboration and clinical research, we are strengthening the evidence and tools supporting eye care practitioners across the continuum of care,” said Olga Prenat, Global Head of Medical and Professional Affairs, EssilorLuxottica.
In parallel, a Continuing Education seminar with a local professional association engaged more than 600 eye care professionals, marking the introduction of spectacle lenses with H.A.L.T.* MAX technology in Hong Kong.
Through contributions at both scientific and clinical levels, EssilorLuxottica advances professional education and scientific exchange in myopia management, reinforcing its commitment to supporting eye care practitioners and advancing eye and vision care responsibly.
Notes
* H.A.L.T. Highly Aspherical Lenslet Target. H.A.L.T. is an acronym for Highly Aspherical Lenslet Target and does not imply a “halt” or “stop” of myopia progression.
† Essilor Stellest lens regulatory status and product availability may vary by country. U.S. FDA authorization and indications for use are based solely on clinical trial data from the U.S.
‡ Essilor Stellest 2.0 lenses are not currently available in all countries, including the U.S. and have not been cleared by the U.S. FDA.
§ Based on 12-month results from a prospective, randomized, double masked contralateral crossover clinical trial conducted in Singapore on 50 children.
¶ Based on 12-month results from a prospective, randomized, double-masked contralateral crossover clinical trial conducted in Singapore on 50 myopic children. The estimated cumulative 1-year axial length change (eye growth) was 0.228 mm with Essilor® Stellest® lenses and 0.121 mm with Essilor Stellest 2.0 lenses, corresponding to a 46 % relative reduction.
References
1.Raveendran RN, et al. Effect of increased power and asphericity of highly aspherical lenslets on myopia control efficacy: a contralateral crossover study. Transl Vis Sci Technol. 2025;14(11):9.
